National Cancer Institute, Naples: Carcinoma, Non-Small-Cell Lung trials

The registry lists 11 Carcinoma, Non-Small-Cell Lung studies with National Cancer Institute, Naples as lead sponsor. 0 are open to participants now and 0 have results posted.

Phase 2 4Phase 3 7No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study Comparing Immunotherapy With Chemotherapy in the Treatment of Elderly Patients With Advanced NSCLC (MILES-5)Status unknownNCT03975114Phase 2
• Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung CancerStatus unknownNCT02633189Phase 3
• PET/CT Scan as a Tool to Rationalize the Treatment of of Advanced NSCLC Patients Undergoing First ChemotherapyStatus unknownNCT02035683Not applicable
• MILES-4: Study Comparing Gemcitabine and Pemetrexed, With or Without Cisplatin, in Patients With Nonsquamous Lung CancerStatus unknownNCT01656551Phase 3
• MILES-3: Cisplatin in Combination With Gemcitabine for Elderly Patients With Lung CancerStatus unknownNCT01405586Phase 3
• CAPPA-2: Cisplatin Added to Gemcitabine in Poor Performance Advanced NSCLC PatientsTerminatedNCT00526643Phase 3
• MILES-02: Study of Chemotherapy Treatment and Toxicity in Elderly Patients With Advanced Non Small Cell Lung CancerCompletedNCT00401492Phase 2
• Study of Rofecoxib and Prolonged Constant Infusion of Gemcitabine in the Polychemotherapy Treatment of Advanced NSCLCCompletedNCT00385606Phase 2/3
• TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung CancerCompletedNCT00349219Phase 3
• The DISTAL-2 Study: Docetaxel Alone or in Combination in Second-line Treatment of Advanced Non Small-Cell Lung CancerTerminatedNCT00345059Phase 3
• CALC-1 (Cetuximab in Advanced Lung Cancer): Study of 2 Methods of Combining Cetuximab and Gemcitabine in Patients With Advanced Non Small-cell Lung CancerCompletedNCT00330746Phase 2